ADC Landscape
AstraZeneca / Daiichi
TROP2 · HR+ breast, NSCLC
ApprovedAntibody–Drug Conjugates
Target
TROP2
Payload
Deruxtecan (DXd)
Payload class
Topo-I inhibitor
Linker
Cleavable tetrapeptide
Indication
HR+ breast, NSCLC
Phase
Approved
Partner
AstraZeneca
Overview
DXd payload on a TROP2 antibody — the direct challenger to Trodelvy. Approved in HR+/HER2- breast; lung program reshaping the TROP2 race.
Technology
AstraZeneca / Daiichi works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Roche / Genentech
HER2
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.